APO Research
Talk to an analyst

APO RESEARCH · REPORT

Restless Legs Syndrome

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Restless Legs Syndrome Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchRestless Legs Syndrome Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Restless Legs Syndrome Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Restless Legs Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Restless Legs Syndrome Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Restless Legs Syndrome Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Restless Legs Syndrome market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Restless Legs Syndrome is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Restless Legs Syndrome market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Restless Legs Syndrome market include UCB SA, Omeros Corporation, Manhattan Pharmaceuticals, Ligand Pharmaceuticals Incorporated, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., GlaxoSmithKline plc., Boehringer Ingelheim GmbH and axxonis Pharma AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Restless Legs Syndrome market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Restless Legs Syndrome and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Restless Legs Syndrome revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Restless Legs Syndrome market.

Restless Legs Syndrome Segment by Company

UCB SA

Omeros Corporation

Manhattan Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Kyowa Hakko Kirin Co.

Jazz Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Boehringer Ingelheim GmbH

axxonis Pharma AG

Astellas

Arbor Pharmaceuticals

Restless Legs Syndrome Segment by Type

Pharmacological Therapy

Non-Pharmacological Therapy

Restless Legs Syndrome Segment by Application

Above 50 Years Old

Below 35 Years Old

From 35 to 50 Years Old

Restless Legs Syndrome Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Restless Legs Syndrome status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Restless Legs Syndrome key companies, revenue, market share, and recent developments.

3. To split the Restless Legs Syndrome breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Restless Legs Syndrome market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Restless Legs Syndrome significant trends, drivers, influence factors in global and regions.

6. To analyze Restless Legs Syndrome competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Restless Legs Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Restless Legs Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Restless Legs Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Restless Legs Syndrome industry.

Chapter 3: Detailed analysis of Restless Legs Syndrome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Restless Legs Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Restless Legs Syndrome in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Restless Legs Syndrome Industry Trends Table 2. Restless Legs Syndrome Industry Drivers Table 3. Restless Legs Syndrome Industry Opportunities and Challenges Table 4. Restless Legs Syndrome Industry Restraints Table 5. Global Restless Legs Syndrome Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Restless Legs Syndrome Revenue Share by Company (2021-2026) Table 7. Global Restless Legs Syndrome Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Restless Legs Syndrome Key Company Manufacturing Base & Headquarters Table 9. Global Restless Legs Syndrome Company, Product Type & Application Table 10. Global Restless Legs Syndrome Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Restless Legs Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pharmacological Therapy Table 15. Significant Companies of Non-Pharmacological Therapy Table 16. Global Restless Legs Syndrome Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Restless Legs Syndrome Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Restless Legs Syndrome Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Restless Legs Syndrome Sales Value Share by Type (2021-2026) Table 20. Global Restless Legs Syndrome Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Above 50 Years Old Table 22. Significant Companies of Below 35 Years Old Table 23. Significant Companies of From 35 to 50 Years Old Table 24. Global Restless Legs Syndrome Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Restless Legs Syndrome Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Restless Legs Syndrome Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Restless Legs Syndrome Sales Value Share by Application (2021-2026) Table 28. Global Restless Legs Syndrome Sales Value Share by Application (2027-2032) Table 29. Global Restless Legs Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Restless Legs Syndrome Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Restless Legs Syndrome Sales Value Share by Region (2021-2026) Table 32. Global Restless Legs Syndrome Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Restless Legs Syndrome Sales Value Share by Region (2027-2032) Table 34. Global Restless Legs Syndrome Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Restless Legs Syndrome Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Restless Legs Syndrome Sales Value Market Share by Country (2021-2026) Table 37. Global Restless Legs Syndrome Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Restless Legs Syndrome Sales Value Market Share by Country (2027-2032) Table 39. UCB SA Company Information Table 40. UCB SA Business Overview Table 41. UCB SA Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. UCB SA Restless Legs Syndrome Product Portfolio Table 43. UCB SA Recent Development Table 44. Omeros Corporation Company Information Table 45. Omeros Corporation Business Overview Table 46. Omeros Corporation Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Omeros Corporation Restless Legs Syndrome Product Portfolio Table 48. Omeros Corporation Recent Development Table 49. Manhattan Pharmaceuticals Company Information Table 50. Manhattan Pharmaceuticals Business Overview Table 51. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 53. Manhattan Pharmaceuticals Recent Development Table 54. Ligand Pharmaceuticals Incorporated Company Information Table 55. Ligand Pharmaceuticals Incorporated Business Overview Table 56. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio Table 58. Ligand Pharmaceuticals Incorporated Recent Development Table 59. Kyowa Hakko Kirin Co. Company Information Table 60. Kyowa Hakko Kirin Co. Business Overview Table 61. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio Table 63. Kyowa Hakko Kirin Co. Recent Development Table 64. Jazz Pharmaceuticals, Inc. Company Information Table 65. Jazz Pharmaceuticals, Inc. Business Overview Table 66. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio Table 68. Jazz Pharmaceuticals, Inc. Recent Development Table 69. GlaxoSmithKline plc. Company Information Table 70. GlaxoSmithKline plc. Business Overview Table 71. GlaxoSmithKline plc. Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio Table 73. GlaxoSmithKline plc. Recent Development Table 74. Boehringer Ingelheim GmbH Company Information Table 75. Boehringer Ingelheim GmbH Business Overview Table 76. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio Table 78. Boehringer Ingelheim GmbH Recent Development Table 79. axxonis Pharma AG Company Information Table 80. axxonis Pharma AG Business Overview Table 81. axxonis Pharma AG Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. axxonis Pharma AG Restless Legs Syndrome Product Portfolio Table 83. axxonis Pharma AG Recent Development Table 84. Astellas Company Information Table 85. Astellas Business Overview Table 86. Astellas Restless Legs Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Astellas Restless Legs Syndrome Product Portfolio Table 88. Astellas Recent Development Table 89. Arbor Pharmaceuticals Company Information Table 90. Arbor Pharmaceuticals Business Overview Table 91. Arbor Pharmaceuticals Restless Legs Syndrome Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio Table 93. Arbor Pharmaceuticals Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Restless Legs Syndrome Product Image Figure 2. Global Restless Legs Syndrome Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Restless Legs Syndrome Market Size (2021-2032) & (US$ Million) Figure 4. Global Restless Legs Syndrome Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pharmacological Therapy Image Figure 8. Non-Pharmacological Therapy Image Figure 9. Global Restless Legs Syndrome Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Restless Legs Syndrome Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Restless Legs Syndrome Sales Value Share by Type (2021-2032) Figure 12. Above 50 Years Old Image Figure 13. Below 35 Years Old Image Figure 14. From 35 to 50 Years Old Image Figure 15. Global Restless Legs Syndrome Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Restless Legs Syndrome Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Restless Legs Syndrome Sales Value Share by Application (2021-2032) Figure 18. Global Restless Legs Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Restless Legs Syndrome Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Restless Legs Syndrome Sales Value (2021-2032) & (US$ Million) Figure 21. North America Restless Legs Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Restless Legs Syndrome Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Restless Legs Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Restless Legs Syndrome Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Restless Legs Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Restless Legs Syndrome Sales Value (2021-2032) & (US$ Million) Figure 27. South America Restless Legs Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Restless Legs Syndrome Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Restless Legs Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Restless Legs Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmacological Therapy
  • Non-Pharmacological Therapy
Applications
  • Above 50 Years Old
  • Below 35 Years Old
  • From 35 to 50 Years Old
Companies covered
  • UCB SA
  • Omeros Corporation
  • Manhattan Pharmaceuticals
  • Ligand Pharmaceuticals Incorporated
  • Kyowa Hakko Kirin Co.
  • Jazz Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Boehringer Ingelheim GmbH
  • axxonis Pharma AG
  • Astellas
  • Arbor Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Restless Legs Syndrome Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Restless Legs Syndrome Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Restless Legs Syndrome Market Dynamics
  1. 2.1 Restless Legs Syndrome Industry Trends
  2. 2.2 Restless Legs Syndrome Industry Drivers
  3. 2.3 Restless Legs Syndrome Industry Opportunities and Challenges
  4. 2.4 Restless Legs Syndrome Industry Restraints
3 Restless Legs Syndrome Market by Company
  1. 3.1 Global Restless Legs Syndrome Company Revenue Ranking in 2025
  2. 3.2 Global Restless Legs Syndrome Revenue by Company (2021-2026)
  3. 3.3 Global Restless Legs Syndrome Company Ranking (2024-2026)
  4. 3.4 Global Restless Legs Syndrome Company Manufacturing Base and Headquarters
  5. 3.5 Global Restless Legs Syndrome Company Product Type and Application
  6. 3.6 Global Restless Legs Syndrome Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Restless Legs Syndrome Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Restless Legs Syndrome Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Restless Legs Syndrome Market by Type
  1. 4.1 Restless Legs Syndrome Type Introduction
  2. 4.1.1 Pharmacological Therapy
  3. 4.1.2 Non-Pharmacological Therapy
  4. 4.2 Global Restless Legs Syndrome Sales Value by Type
  5. 4.2.1 Global Restless Legs Syndrome Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Restless Legs Syndrome Sales Value by Type (2021-2032)
  7. 4.2.3 Global Restless Legs Syndrome Sales Value Share by Type (2021-2032)
5 Restless Legs Syndrome Market by Application
  1. 5.1 Restless Legs Syndrome Application Introduction
  2. 5.1.1 Above 50 Years Old
  3. 5.1.2 Below 35 Years Old
  4. 5.1.3 From 35 to 50 Years Old
  5. 5.2 Global Restless Legs Syndrome Sales Value by Application
  6. 5.2.1 Global Restless Legs Syndrome Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Restless Legs Syndrome Sales Value by Application (2021-2032)
  8. 5.2.3 Global Restless Legs Syndrome Sales Value Share by Application (2021-2032)
6 Restless Legs Syndrome Regional Value Analysis
  1. 6.1 Global Restless Legs Syndrome Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Restless Legs Syndrome Sales Value by Region (2021-2032)
  3. 6.2.1 Global Restless Legs Syndrome Sales Value by Region: 2021-2026
  4. 6.2.2 Global Restless Legs Syndrome Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Restless Legs Syndrome Sales Value (2021-2032)
  7. 6.3.2 North America Restless Legs Syndrome Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Restless Legs Syndrome Sales Value (2021-2032)
  10. 6.4.2 Europe Restless Legs Syndrome Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Restless Legs Syndrome Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Restless Legs Syndrome Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Restless Legs Syndrome Sales Value (2021-2032)
  16. 6.6.2 South America Restless Legs Syndrome Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Restless Legs Syndrome Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Restless Legs Syndrome Sales Value Share by Country, 2025 VS 2032
7 Restless Legs Syndrome Country-level Value Analysis
  1. 7.1 Global Restless Legs Syndrome Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Restless Legs Syndrome Sales Value by Country (2021-2032)
  3. 7.2.1 Global Restless Legs Syndrome Sales Value by Country (2021-2026)
  4. 7.2.2 Global Restless Legs Syndrome Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Restless Legs Syndrome Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Restless Legs Syndrome Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Restless Legs Syndrome Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 UCB SA
  2. 8.1.1 UCB SA Company Information
  3. 8.1.2 UCB SA Business Overview
  4. 8.1.3 UCB SA Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  5. 8.1.4 UCB SA Restless Legs Syndrome Product Portfolio
  6. 8.1.5 UCB SA Recent Developments
  7. 8.2 Omeros Corporation
  8. 8.2.1 Omeros Corporation Company Information
  9. 8.2.2 Omeros Corporation Business Overview
  10. 8.2.3 Omeros Corporation Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Omeros Corporation Restless Legs Syndrome Product Portfolio
  12. 8.2.5 Omeros Corporation Recent Developments
  13. 8.3 Manhattan Pharmaceuticals
  14. 8.3.1 Manhattan Pharmaceuticals Company Information
  15. 8.3.2 Manhattan Pharmaceuticals Business Overview
  16. 8.3.3 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Manhattan Pharmaceuticals Restless Legs Syndrome Product Portfolio
  18. 8.3.5 Manhattan Pharmaceuticals Recent Developments
  19. 8.4 Ligand Pharmaceuticals Incorporated
  20. 8.4.1 Ligand Pharmaceuticals Incorporated Company Information
  21. 8.4.2 Ligand Pharmaceuticals Incorporated Business Overview
  22. 8.4.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product Portfolio
  24. 8.4.5 Ligand Pharmaceuticals Incorporated Recent Developments
  25. 8.5 Kyowa Hakko Kirin Co.
  26. 8.5.1 Kyowa Hakko Kirin Co. Company Information
  27. 8.5.2 Kyowa Hakko Kirin Co. Business Overview
  28. 8.5.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product Portfolio
  30. 8.5.5 Kyowa Hakko Kirin Co. Recent Developments
  31. 8.6 Jazz Pharmaceuticals, Inc.
  32. 8.6.1 Jazz Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Jazz Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product Portfolio
  36. 8.6.5 Jazz Pharmaceuticals, Inc. Recent Developments
  37. 8.7 GlaxoSmithKline plc.
  38. 8.7.1 GlaxoSmithKline plc. Company Information
  39. 8.7.2 GlaxoSmithKline plc. Business Overview
  40. 8.7.3 GlaxoSmithKline plc. Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc. Restless Legs Syndrome Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc. Recent Developments
  43. 8.8 Boehringer Ingelheim GmbH
  44. 8.8.1 Boehringer Ingelheim GmbH Company Information
  45. 8.8.2 Boehringer Ingelheim GmbH Business Overview
  46. 8.8.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Product Portfolio
  48. 8.8.5 Boehringer Ingelheim GmbH Recent Developments
  49. 8.9 axxonis Pharma AG
  50. 8.9.1 axxonis Pharma AG Company Information
  51. 8.9.2 axxonis Pharma AG Business Overview
  52. 8.9.3 axxonis Pharma AG Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  53. 8.9.4 axxonis Pharma AG Restless Legs Syndrome Product Portfolio
  54. 8.9.5 axxonis Pharma AG Recent Developments
  55. 8.10 Astellas
  56. 8.10.1 Astellas Company Information
  57. 8.10.2 Astellas Business Overview
  58. 8.10.3 Astellas Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Astellas Restless Legs Syndrome Product Portfolio
  60. 8.10.5 Astellas Recent Developments
  61. 8.11 Arbor Pharmaceuticals
  62. 8.11.1 Arbor Pharmaceuticals Company Information
  63. 8.11.2 Arbor Pharmaceuticals Business Overview
  64. 8.11.3 Arbor Pharmaceuticals Restless Legs Syndrome Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Arbor Pharmaceuticals Restless Legs Syndrome Product Portfolio
  66. 8.11.5 Arbor Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst